Table 3. Open in new tab Performance of...

	AUC (95% CI)	ACC (95% CI), %	SN (95% CI), %	SP (95% CI), %	PPV (95% CI), %	NPV (95% CI), %	Kappa	F1	AUC P-value
Endometriosis
TEPOC	0.899 (0.830–0.968)	86.6 (80.4–91.4)	89.0 (82.2–93.8)	78.4 (61.8–90.2)	93.4 (87.4–97.1)	67.4 (51.5–80.9)	0.637	0.911	<0.001
CA125	0.659 (0.568–0.750)	70.1 (62.5–77.0)	80.3 (72.3–86.8)	35.1 (20.2–52.5)	81.0 (73.0–87.4)	34.2 (19.6–51.4)	0.153	0.806	—
TEPOC+CA125	0.897 (0.832–0.963)	87.8 (81.8–92.4)	90.6 (84.1–95.0)	78.4 (61.8–90.2)	93.5 (87.6–97.2)	70.7 (54.5–83.9)	0.664	0.920	<0.001
Borderline
TEPOC	0.859 (0.789–0.929)	76.7 (69.1–83.2)	76.7 (61.4–88.2)	76.6 (67.5–84.3)	56.9 (43.2–69.8)	89.1 (80.9–94.7)	0.483	0.653	0.155
CA125	0.780 (0.696–0.864)	73.4 (65.4–80.5)	74.4 (58.8–86.5)	73.0 (63.2–81.4)	54.2 (40.8–67.3)	86.9 (77.8–93.3)	0.429	0.627	—
TEPOC+CA125	0.885 (0.819–0.951)	83.2 (76.1–88.9)	76.7 (61.4–88.2)	86.0 (77.6–92.1)	70.2 (55.1–82.7)	89.6 (81.7–94.9)	0.611	0.733	0.017
Early stage
TEPOC	0.858 (0.790–0.926)	75.7 (67.9–82.3)	73.2 (57.1–85.8)	76.6 (67.5–84.3)	54.5 (40.6–68.0)	88.2 (79.8–93.9)	0.451	0.625	0.060
CA125	0.749 (0.660–0.839)	70.9 (62.7–78.3)	65.9 (49.4–79.9)	73.0 (63.2–81.4)	50.0 (36.1–63.9)	83.9 (74.5–90.9)	0.355	0.568	—
TEPOC+CA125	0.879 (0.813–0.944)	82.3 (74.9–88.2)	73.2 (57.1–85.8)	86.0 (77.6–92.1)	68.2 (52.4–81.4)	88.7 (80.6–94.2)	0.579	0.706	0.005
Non-epithelial
TEPOC	0.920 (0.868–0.972)	79.3 (70.8–86.3)	82.6 (61.2–95.0)	78.5 (68.8–86.3)	48.7 (32.4–65.2)	94.8 (87.2–98.6)	0.484	0.613	0.002
CA125	0.751 (0.651–0.850)	70.7 (61.5–78.8)	60.9 (38.5–80.3)	73.1 (62.9–81.8)	35.9 (21.2–52.8)	88.3 (79.0–94.5)	0.269	0.452	—
TEPOC+CA125	0.926 (0.875–0.977)	85.3 (77.6–91.2)	87.0 (66.4–97.2)	84.9 (76.0–91.5)	58.8 (40.7–75.4)	96.3 (89.7–99.2)	0.609	0.702	<0.001

AUC (95% CI)

ACC (95% CI), %

SN (95% CI), %

SP (95% CI), %

PPV (95% CI), %

NPV (95% CI), %

Kappa

AUC
P-value

Endometriosis

TEPOC

0.899 (0.830–0.968)

86.6 (80.4–91.4)

89.0 (82.2–93.8)

78.4 (61.8–90.2)

93.4 (87.4–97.1)

67.4 (51.5–80.9)

0.637

0.911

<0.001

CA125

0.659 (0.568–0.750)

70.1 (62.5–77.0)

80.3 (72.3–86.8)

35.1 (20.2–52.5)

81.0 (73.0–87.4)

34.2 (19.6–51.4)

0.153

0.806

—

TEPOC+CA125

0.897 (0.832–0.963)

87.8 (81.8–92.4)

90.6 (84.1–95.0)

78.4 (61.8–90.2)

93.5 (87.6–97.2)

70.7 (54.5–83.9)

0.664

0.920

<0.001

Borderline

TEPOC

0.859 (0.789–0.929)

76.7 (69.1–83.2)

76.7 (61.4–88.2)

76.6 (67.5–84.3)

56.9 (43.2–69.8)

89.1 (80.9–94.7)

0.483

0.653

0.155

CA125

0.780 (0.696–0.864)

73.4 (65.4–80.5)

74.4 (58.8–86.5)

73.0 (63.2–81.4)

54.2 (40.8–67.3)

86.9 (77.8–93.3)

0.429

0.627

—

TEPOC+CA125

0.885 (0.819–0.951)

83.2 (76.1–88.9)

76.7 (61.4–88.2)

86.0 (77.6–92.1)

70.2 (55.1–82.7)

89.6 (81.7–94.9)

0.611

0.733

0.017

Early stage

TEPOC

0.858 (0.790–0.926)

75.7 (67.9–82.3)

73.2 (57.1–85.8)

76.6 (67.5–84.3)

54.5 (40.6–68.0)

88.2 (79.8–93.9)

0.451

0.625

0.060

CA125

0.749 (0.660–0.839)

70.9 (62.7–78.3)

65.9 (49.4–79.9)

73.0 (63.2–81.4)

50.0 (36.1–63.9)

83.9 (74.5–90.9)

0.355

0.568

—

TEPOC+CA125

0.879 (0.813–0.944)

82.3 (74.9–88.2)

73.2 (57.1–85.8)

86.0 (77.6–92.1)

68.2 (52.4–81.4)

88.7 (80.6–94.2)

0.579

0.706

0.005

Non-epithelial

TEPOC

0.920 (0.868–0.972)

79.3 (70.8–86.3)

82.6 (61.2–95.0)

78.5 (68.8–86.3)

48.7 (32.4–65.2)

94.8 (87.2–98.6)

0.484

0.613

0.002

CA125

0.751 (0.651–0.850)

70.7 (61.5–78.8)

60.9 (38.5–80.3)

73.1 (62.9–81.8)

35.9 (21.2–52.8)

88.3 (79.0–94.5)

0.269

0.452

—

TEPOC+CA125

0.926 (0.875–0.977)

85.3 (77.6–91.2)

87.0 (66.4–97.2)

84.9 (76.0–91.5)

58.8 (40.7–75.4)

96.3 (89.7–99.2)

0.609

0.702

<0.001

	AUC (95% CI)	ACC (95% CI), %	SN (95% CI), %	SP (95% CI), %	PPV (95% CI), %	NPV (95% CI), %	Kappa	F1	AUC P-value
Endometriosis
TEPOC	0.899 (0.830–0.968)	86.6 (80.4–91.4)	89.0 (82.2–93.8)	78.4 (61.8–90.2)	93.4 (87.4–97.1)	67.4 (51.5–80.9)	0.637	0.911	<0.001
CA125	0.659 (0.568–0.750)	70.1 (62.5–77.0)	80.3 (72.3–86.8)	35.1 (20.2–52.5)	81.0 (73.0–87.4)	34.2 (19.6–51.4)	0.153	0.806	—
TEPOC+CA125	0.897 (0.832–0.963)	87.8 (81.8–92.4)	90.6 (84.1–95.0)	78.4 (61.8–90.2)	93.5 (87.6–97.2)	70.7 (54.5–83.9)	0.664	0.920	<0.001
Borderline
TEPOC	0.859 (0.789–0.929)	76.7 (69.1–83.2)	76.7 (61.4–88.2)	76.6 (67.5–84.3)	56.9 (43.2–69.8)	89.1 (80.9–94.7)	0.483	0.653	0.155
CA125	0.780 (0.696–0.864)	73.4 (65.4–80.5)	74.4 (58.8–86.5)	73.0 (63.2–81.4)	54.2 (40.8–67.3)	86.9 (77.8–93.3)	0.429	0.627	—
TEPOC+CA125	0.885 (0.819–0.951)	83.2 (76.1–88.9)	76.7 (61.4–88.2)	86.0 (77.6–92.1)	70.2 (55.1–82.7)	89.6 (81.7–94.9)	0.611	0.733	0.017
Early stage
TEPOC	0.858 (0.790–0.926)	75.7 (67.9–82.3)	73.2 (57.1–85.8)	76.6 (67.5–84.3)	54.5 (40.6–68.0)	88.2 (79.8–93.9)	0.451	0.625	0.060
CA125	0.749 (0.660–0.839)	70.9 (62.7–78.3)	65.9 (49.4–79.9)	73.0 (63.2–81.4)	50.0 (36.1–63.9)	83.9 (74.5–90.9)	0.355	0.568	—
TEPOC+CA125	0.879 (0.813–0.944)	82.3 (74.9–88.2)	73.2 (57.1–85.8)	86.0 (77.6–92.1)	68.2 (52.4–81.4)	88.7 (80.6–94.2)	0.579	0.706	0.005
Non-epithelial
TEPOC	0.920 (0.868–0.972)	79.3 (70.8–86.3)	82.6 (61.2–95.0)	78.5 (68.8–86.3)	48.7 (32.4–65.2)	94.8 (87.2–98.6)	0.484	0.613	0.002
CA125	0.751 (0.651–0.850)	70.7 (61.5–78.8)	60.9 (38.5–80.3)	73.1 (62.9–81.8)	35.9 (21.2–52.8)	88.3 (79.0–94.5)	0.269	0.452	—
TEPOC+CA125	0.926 (0.875–0.977)	85.3 (77.6–91.2)	87.0 (66.4–97.2)	84.9 (76.0–91.5)	58.8 (40.7–75.4)	96.3 (89.7–99.2)	0.609	0.702	<0.001

Table 3.

Open in new tab

Performance of TEPOC and CA125 to detect ovarian cancer in subgroup analysis.

	AUC (95% CI)	ACC (95% CI), %	SN (95% CI), %	SP (95% CI), %	PPV (95% CI), %	NPV (95% CI), %	Kappa	F1	AUC P-value
Endometriosis
TEPOC	0.899 (0.830–0.968)	86.6 (80.4–91.4)	89.0 (82.2–93.8)	78.4 (61.8–90.2)	93.4 (87.4–97.1)	67.4 (51.5–80.9)	0.637	0.911	<0.001
CA125	0.659 (0.568–0.750)	70.1 (62.5–77.0)	80.3 (72.3–86.8)	35.1 (20.2–52.5)	81.0 (73.0–87.4)	34.2 (19.6–51.4)	0.153	0.806	—
TEPOC+CA125	0.897 (0.832–0.963)	87.8 (81.8–92.4)	90.6 (84.1–95.0)	78.4 (61.8–90.2)	93.5 (87.6–97.2)	70.7 (54.5–83.9)	0.664	0.920	<0.001
Borderline
TEPOC	0.859 (0.789–0.929)	76.7 (69.1–83.2)	76.7 (61.4–88.2)	76.6 (67.5–84.3)	56.9 (43.2–69.8)	89.1 (80.9–94.7)	0.483	0.653	0.155
CA125	0.780 (0.696–0.864)	73.4 (65.4–80.5)	74.4 (58.8–86.5)	73.0 (63.2–81.4)	54.2 (40.8–67.3)	86.9 (77.8–93.3)	0.429	0.627	—
TEPOC+CA125	0.885 (0.819–0.951)	83.2 (76.1–88.9)	76.7 (61.4–88.2)	86.0 (77.6–92.1)	70.2 (55.1–82.7)	89.6 (81.7–94.9)	0.611	0.733	0.017
Early stage
TEPOC	0.858 (0.790–0.926)	75.7 (67.9–82.3)	73.2 (57.1–85.8)	76.6 (67.5–84.3)	54.5 (40.6–68.0)	88.2 (79.8–93.9)	0.451	0.625	0.060
CA125	0.749 (0.660–0.839)	70.9 (62.7–78.3)	65.9 (49.4–79.9)	73.0 (63.2–81.4)	50.0 (36.1–63.9)	83.9 (74.5–90.9)	0.355	0.568	—
TEPOC+CA125	0.879 (0.813–0.944)	82.3 (74.9–88.2)	73.2 (57.1–85.8)	86.0 (77.6–92.1)	68.2 (52.4–81.4)	88.7 (80.6–94.2)	0.579	0.706	0.005
Non-epithelial
TEPOC	0.920 (0.868–0.972)	79.3 (70.8–86.3)	82.6 (61.2–95.0)	78.5 (68.8–86.3)	48.7 (32.4–65.2)	94.8 (87.2–98.6)	0.484	0.613	0.002
CA125	0.751 (0.651–0.850)	70.7 (61.5–78.8)	60.9 (38.5–80.3)	73.1 (62.9–81.8)	35.9 (21.2–52.8)	88.3 (79.0–94.5)	0.269	0.452	—
TEPOC+CA125	0.926 (0.875–0.977)	85.3 (77.6–91.2)	87.0 (66.4–97.2)	84.9 (76.0–91.5)	58.8 (40.7–75.4)	96.3 (89.7–99.2)	0.609	0.702	<0.001

	AUC (95% CI)	ACC (95% CI), %	SN (95% CI), %	SP (95% CI), %	PPV (95% CI), %	NPV (95% CI), %	Kappa	F1	AUC P-value
Endometriosis
TEPOC	0.899 (0.830–0.968)	86.6 (80.4–91.4)	89.0 (82.2–93.8)	78.4 (61.8–90.2)	93.4 (87.4–97.1)	67.4 (51.5–80.9)	0.637	0.911	<0.001
CA125	0.659 (0.568–0.750)	70.1 (62.5–77.0)	80.3 (72.3–86.8)	35.1 (20.2–52.5)	81.0 (73.0–87.4)	34.2 (19.6–51.4)	0.153	0.806	—
TEPOC+CA125	0.897 (0.832–0.963)	87.8 (81.8–92.4)	90.6 (84.1–95.0)	78.4 (61.8–90.2)	93.5 (87.6–97.2)	70.7 (54.5–83.9)	0.664	0.920	<0.001
Borderline
TEPOC	0.859 (0.789–0.929)	76.7 (69.1–83.2)	76.7 (61.4–88.2)	76.6 (67.5–84.3)	56.9 (43.2–69.8)	89.1 (80.9–94.7)	0.483	0.653	0.155
CA125	0.780 (0.696–0.864)	73.4 (65.4–80.5)	74.4 (58.8–86.5)	73.0 (63.2–81.4)	54.2 (40.8–67.3)	86.9 (77.8–93.3)	0.429	0.627	—
TEPOC+CA125	0.885 (0.819–0.951)	83.2 (76.1–88.9)	76.7 (61.4–88.2)	86.0 (77.6–92.1)	70.2 (55.1–82.7)	89.6 (81.7–94.9)	0.611	0.733	0.017
Early stage
TEPOC	0.858 (0.790–0.926)	75.7 (67.9–82.3)	73.2 (57.1–85.8)	76.6 (67.5–84.3)	54.5 (40.6–68.0)	88.2 (79.8–93.9)	0.451	0.625	0.060
CA125	0.749 (0.660–0.839)	70.9 (62.7–78.3)	65.9 (49.4–79.9)	73.0 (63.2–81.4)	50.0 (36.1–63.9)	83.9 (74.5–90.9)	0.355	0.568	—
TEPOC+CA125	0.879 (0.813–0.944)	82.3 (74.9–88.2)	73.2 (57.1–85.8)	86.0 (77.6–92.1)	68.2 (52.4–81.4)	88.7 (80.6–94.2)	0.579	0.706	0.005
Non-epithelial
TEPOC	0.920 (0.868–0.972)	79.3 (70.8–86.3)	82.6 (61.2–95.0)	78.5 (68.8–86.3)	48.7 (32.4–65.2)	94.8 (87.2–98.6)	0.484	0.613	0.002
CA125	0.751 (0.651–0.850)	70.7 (61.5–78.8)	60.9 (38.5–80.3)	73.1 (62.9–81.8)	35.9 (21.2–52.8)	88.3 (79.0–94.5)	0.269	0.452	—
TEPOC+CA125	0.926 (0.875–0.977)	85.3 (77.6–91.2)	87.0 (66.4–97.2)	84.9 (76.0–91.5)	58.8 (40.7–75.4)	96.3 (89.7–99.2)	0.609	0.702	<0.001

Endometriosis cohort (endometriosis n = 37 vs. ovarian cancer n = 127). Borderline cohort (borderline ovarian tumors n = 43 vs. BAM n = 107). Early-stage cohort (early-stage ovarian cancer n = 41 vs. BAM n = 107). Non-epithelial cohort (non-epithelial malignancies n = 23 vs. BAM n = 93). Predictions of TEPOC and the combination were compared with those of CA125 using a two-sided DeLong’s test. Abbreviations: BAM, benign adnexal mass. TEPOC, tumor-educated platelet-derived gene panel of ovarian cancer; CA125, cancer antigen 125; TEPOC+CA125, the combination of TEPOC and CA125; AUC, area under the curve; ACC, accuracy; SN, sensitivity; SP, specificity; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval.

This Feature Is Available To Subscribers Only